Bayer, J&J's bid to further widen use of Xarelto hits snag
Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit. The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal, Germany February 24, 2014.
from Biotech News
0 Comments